Relevance of polyclonal plasma cells and post-therapy immunomodulation in measurable residual disease assessment in multiple myeloma.
Nupur DasMeetu DahiyaRitu GuptaLalit KumarAtul SharmaSandeep RaiSaroj SinghVijay K PrajapatiRanjit K SahooAjay GogiaPublished in: Cytometry. Part B, Clinical cytometry (2022)
The panorama and high frequency of antigenic aberrations on polyclonal PC signify the importance of MRD assay validation on a large cohort under normal and reactive conditions. Frequent Immunophenotypic shifts in APC re-confirm the redundancy of baseline immunophenotype for MRD evaluation. Small clones of APC may be missed by assessment of cyKLR alone and therefore, surface marker aberrancy supported by cyLCR is required for definitive assignment of residual APC.
Keyphrases
- high frequency
- transcranial magnetic stimulation
- multiple myeloma
- induced apoptosis
- cell cycle arrest
- stem cells
- high throughput
- signaling pathway
- squamous cell carcinoma
- copy number
- endoplasmic reticulum stress
- mesenchymal stem cells
- oxidative stress
- dna methylation
- locally advanced
- cell proliferation
- genome wide
- cell therapy
- replacement therapy
- clinical evaluation